Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 6/20 | 0.57 |
| ▸ | TK2 | O00142 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374922 | 1.00 | RNASE1 (0.59) | RNASE1TK1TK2 | |
| SCHEMBL31355237 | 0.90 | RNASE1 (0.72) | RNASE1TK1TK2 | |
| SCHEMBL9324697 | 0.89 | RNASE1 (0.58) | RNASE1TK1TK2 | |
| SCHEMBL9017662 | 0.84 | RNASE1 (0.68) | RNASE1TK1TK2 | |
| SCHEMBL9017714 | 0.82 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL12718428 | 0.82 | RNASE1 (0.67) | RNASE1TK1TK2 | |
| SCHEMBL9017697 | 0.81 | RNASE1 (0.61) | RNASE1TK1TK2 | |
| SCHEMBL9755168 | 0.79 | TK1 (0.47) | RNASE1TK1TK2 | |
| SCHEMBL9017722 | 0.79 | RNASE1 (0.63) | RNASE1TK1TK2 | |
| SCHEMBL9550743 | 0.79 | TK1 (0.64) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-0586570-B1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5965721-A | WITH IMPROVED NUCLEASE RESISTANCE AND IMPROVED CELLULAR UPTAKE; FOR ANTISENSE AGENTS AND REGULATION OF RNA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5610289-A | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0586570-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | RNASE1, RNGTT, NSUN2 | RNASE1 1/4885TK1 98/4885TK2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.